JPWO2023041508A5 - - Google Patents

Info

Publication number
JPWO2023041508A5
JPWO2023041508A5 JP2024516476A JP2024516476A JPWO2023041508A5 JP WO2023041508 A5 JPWO2023041508 A5 JP WO2023041508A5 JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024516476 A JP2024516476 A JP 2024516476A JP WO2023041508 A5 JPWO2023041508 A5 JP WO2023041508A5
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotide sequence
molecule
acid molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531728A (ja
JP2024531728A5 (https=
Publication date
Priority claimed from GBGB2113104.0A external-priority patent/GB202113104D0/en
Priority claimed from GBGB2207239.1A external-priority patent/GB202207239D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/075355 external-priority patent/WO2023041508A2/en
Publication of JP2024531728A publication Critical patent/JP2024531728A/ja
Publication of JPWO2023041508A5 publication Critical patent/JPWO2023041508A5/ja
Publication of JP2024531728A5 publication Critical patent/JP2024531728A5/ja
Pending legal-status Critical Current

Links

JP2024516476A 2021-09-14 2022-09-13 心血管疾患の処置 Pending JP2024531728A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2113104.0A GB202113104D0 (en) 2021-09-14 2021-09-14 Antagonist of pcsk9
GB2113104.0 2021-09-14
GBGB2207239.1A GB202207239D0 (en) 2022-05-18 2022-05-18 Treatment of cardiovascular disease 2
GB2207239.1 2022-05-18
PCT/EP2022/075355 WO2023041508A2 (en) 2021-09-14 2022-09-13 Treatment of cardiovascular disease

Publications (3)

Publication Number Publication Date
JP2024531728A JP2024531728A (ja) 2024-08-29
JPWO2023041508A5 true JPWO2023041508A5 (https=) 2025-07-23
JP2024531728A5 JP2024531728A5 (https=) 2025-07-23

Family

ID=83691543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516476A Pending JP2024531728A (ja) 2021-09-14 2022-09-13 心血管疾患の処置

Country Status (5)

Country Link
US (1) US20250283076A1 (https=)
EP (1) EP4402263A2 (https=)
JP (1) JP2024531728A (https=)
CA (1) CA3229020A1 (https=)
WO (1) WO2023041508A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
EP4680740A1 (en) * 2023-03-14 2026-01-21 Argonaute Rna Limited Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule
WO2024228030A2 (en) * 2023-05-04 2024-11-07 Argonaute RNA Limited Dual silencing
WO2024245151A1 (zh) * 2023-05-26 2024-12-05 维亚臻生物技术（苏州）有限公司 一种用于代谢疾病的双链核苷酸化合物及其应用
AU2024321098A1 (en) * 2023-08-09 2026-03-19 Beijing Foyou Pharma Co., Ltd Sirna for inhibiting dgat2 gene expression, sirna conjugate or prodrug and pharmaceutical composition thereof, and use thereof
WO2025040139A1 (zh) * 2023-08-23 2025-02-27 云合智药（苏州）生物科技有限公司 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用
WO2025103391A1 (zh) * 2023-11-15 2025-05-22 北京加科瑞康医药科技有限公司 用于抑制lpa的基因表达的sirna，含其的组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064008A2 (en) 2000-03-03 2001-09-07 Smithkline Beecham Biologicals S.A. Vaccine for the treatment of artherosclerosis
GB0121171D0 (en) 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
GB0305794D0 (en) 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
WO2005045035A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
ES2804764T3 (es) * 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
WO2012058693A2 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
US10125369B2 (en) * 2012-12-05 2018-11-13 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA compositions and methods of use thereof
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
WO2014205449A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
JOP20160211B1 (ar) 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
BR112019010057A2 (pt) 2016-11-16 2019-09-03 Purdue Research Foundation composição, método para suprimir a ingestão de comida, sequência de shrna, método de inibição da síntese de ácidos graxos
MX2020004897A (es) 2017-11-13 2020-10-05 Silence Therapeutics Gmbh Acidos nucleicos para inhibir la expresion de lpa en una celula.
BR112021009213A2 (pt) * 2018-11-13 2021-08-10 Silence Therapeutics Gmbh ácidos nucleicos para inibição da expressão de lpa em uma célula
US20230027604A1 (en) * 2019-07-02 2023-01-26 Argonaute RNA Limited Apolipoprotein b antagonist
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
US20230183694A1 (en) * 2020-03-16 2023-06-15 Argonaute RNA Limited Antagonist of pcsk9

Similar Documents

Publication Publication Date Title
Gryaznov Oligonucleotide N3′→ P5′ phosphoramidates as potential therapeutic agents
EP2407558A1 (en) Methods for the detection of a single- or double-stranded nucleic acid molecule
PT1527176E (pt) Novas formas de muléculas de arn de interferência
JP2020188756A5 (https=)
CA2785451C (en) Molecule for treating an inflammatory disorder
JP2009514877A5 (https=)
JP2010503382A5 (https=)
JP2011511636A5 (https=)
JP2014527401A5 (https=)
CN105008533A (zh) 嵌合单链反义多核苷酸和双链反义试剂
JP2005517427A5 (https=)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
Toulme et al. Targeting RNA structures by antisense oligonucleotides
JP2010512747A5 (https=)
JP7033591B2 (ja) 治療用オリゴヌクレオチドの捕捉および検出
WO2019196887A1 (zh) 一种新型小激活rna
US20150299707A1 (en) Construction of pool of interfering nucleic acids covering entire rna target sequence and related compositions
JP3721308B2 (ja) より良好な安定性及びアンチセンス効果を有する新規なアンチセンス−オリゴ
JP2003517283A (ja) プライマーペアの増幅及び配列決定並びにそれらの使用
JPWO2023041508A5 (https=)
Zavyalova et al. DNA aptamer-based molecular nanoconstructions and nanodevices for diagnostics and therapy
US9102937B2 (en) Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (TINA) and process for the preparation of TINA
JPWO2022136673A5 (https=)
JPWO2021087036A5 (https=)
CN113453727A (zh) 异源核酸的最适ps修饰模式